Skip to main content
. 2017 Apr 10;8(34):56185–56198. doi: 10.18632/oncotarget.17015

Figure 4. The combination of trastuzumab with NAC supplementation results in a lower 18F-FDG uptake in trastuzumab resistant tumors.

Figure 4

18F-FDG uptake of SKBr3 (HER2+/MUC4-) and JIMT1 (HER2+/MUC4+) tumors in dual-tumor-bearing mice randomized to the four treatment arms CS (Control+Saline; blue, n = 10), CT (Control+Trastuzumab; purple, n = 10), NS (NAC+Saline; green, n = 9) and NT (NAC+Trastuzumab; red n = 10) is represented. (A) The baseline 18F-FDG uptake of JIMT1 and SKBr3 tumors preceding randomization is shown with future treatment group allocation. Representative 18F-FDG PET/CT axial images(left) of the tumor (arrow) before and after treatment are shown together with the changes in 18F-FDG uptake represented as percentage difference in SUVmax (%ΔSUVmax, right) for (B) JIMT1 and SKBr3 tumors in the different treatment arms. Data points as well as mean ± SEM are shown. Data are expressed in SUVmax for the baseline 18F-FDG uptake or as the percentage difference in SUVmax (%ΔSUVmax) when comparing the effect of the different treatment arms; with **p < 0.01 and ***p < 0.001.